Gilead reports compassionate use data of remdesivir in Covid-19
Gilead Sciences has reported positive data from analysis of an international cohort of patients treated with remdesivir as a potential
Tag: remdesivir
Novartis CEO says Malaria drug biggest hope against coronavirus
Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis. Novartis Chief Executive Vas Narasimhan said his Sandoz
EMA’s recommendation on compassionate use of SBECD-enabled remdesivir for COVID-19 and Update from Gilead
During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral
Race to find COVID-19 treatments accelerates
A recent review in Science [1] reported that WHO on 20 March announced the launch of SOLIDARITY, an unprecedented, coordinated
Gilead to expand access to remdesivir, its promising coronavirus treatment
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug SBECD-enabled remdesivir to accelerate its emergency use for multiple
University Hospitals in US to conduct coronavirus clinical trials
University Hospitals in Cleveland, US is set to conduct two clinical trials of remdesivir to treat adult Covid-19 patients hospitalised
Hundreds of Virus Patients Allowed to Try Gilead’s Ebola Drug
Hundreds of coronavirus patients have been treated with Gilead’s experimental Ebola treatment under an FDA program to allow access to
A CycloLab Kft. felveszi a kesztyűt a koronavírus elleni harcban
Az új koronavírus (SARS-CoV-2) okozta megbetegedés (COVID-19) mára több, mint 65 országot és területet érint, majd 90000 regisztrált megbetegedéssel és
CycloLab picks up the gauntlet to fight coronavirus
The novel coronavirus SARS-CoV-2 is affecting 65 countries and territories around the world with almost 90,000 reported cases and almost
Gilead Sciences Initiates Two Phase 3 Studies of Investigational SBECD-enabled Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of